Caricamento...
Increased MALAT1 expression contributes to cisplatin resistance in non-small cell lung cancer
Cisplatin-based chemotherapy is commonly used for the clinical treatment of patients with non-small cell lung cancer (NSCLC). However, the anti-tumor efficacy of cisplatin is limited by poor clinical response and the development of chemoresistance. At present, the underlying mechanism for cisplatin...
Salvato in:
| Pubblicato in: | Oncol Lett |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
D.A. Spandidos
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6144744/ https://ncbi.nlm.nih.gov/pubmed/30250547 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2018.9293 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|